InMed Pharmaceuticals Inc. Material Event: Nasdaq Compliance Update

This report explains the latest news from InMed Pharmaceuticals in plain English. If you follow the company, here is the essential breakdown of their recent Nasdaq notification.

---

1. What happened?

InMed Pharmaceuticals (Nasdaq: INM) received a formal warning from the Nasdaq Stock Market. Their stock price closed below the $1.00 minimum requirement for 30 consecutive business days. This is a standard notification issued when a company no longer meets the exchange's listing standards.

2. Why did it happen?

Nasdaq requires stocks to trade above $1.00 to maintain market stability. InMed’s share price has faced downward pressure, which is common for clinical-stage biotech companies. These firms often burn through cash to fund research and rely on selling new shares to raise capital, which can dilute existing shareholders and impact the stock price.

3. Why does this matter?

This is a significant warning sign. While InMed continues to trade as "INM," the company is now on a deadline. If they cannot regain compliance, they face delisting. Moving to the "Over-the-Counter" (OTC) market would make the stock harder to trade, reduce interest from large institutional investors, and make it more difficult for the company to raise the capital needed to fund its drug programs.

4. Who is affected?

• Investors: Shareholders may experience increased price volatility. Many large investment funds have mandates that prevent them from holding stocks that aren't on major exchanges, which can sometimes lead to automated selling.
• The Company: Management must now divert focus toward regaining compliance, which takes time away from their core mission of advancing drug candidates like INM-901 for Alzheimer’s or INM-755 for skin conditions.
• Patients: There is no immediate impact on clinical trials or product availability. The company remains fully operational.

5. What happens next?

InMed has 180 days—until September 23, 2026—to fix the issue. To regain compliance, their stock price must close at or above $1.00 for at least 10 consecutive business days.

If they fail to meet this goal, they may be eligible for a second 180-day extension. To achieve this, companies often perform a "reverse stock split," which combines existing shares into fewer, higher-priced shares. While this mathematically boosts the share price, it is often viewed by the market as a sign that the company is struggling to grow its valuation naturally.

6. What should investors know?

• For the casual observer: This is a common hurdle for small biotech firms that are not yet profitable. It highlights that the market is currently skeptical about the company’s near-term progress or its cash runway.
• For the active investor: Keep a close eye on SEC filings for the company’s official plan to regain compliance. Be particularly cautious regarding news of a reverse stock split; these are frequently followed by further share issuances, which can dilute your ownership percentage and put additional downward pressure on the stock price.

---

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and should not be considered financial advice. Always do your own research and consult with a professional before making investment decisions.